NanoMnSor enhances the efficacy of anti-PD-1 antibodies and whole cell cancer vaccine immunotherapy by reducing tumor invasion of hypoxia-induced tumor-associated macrophages, promoting macrophage polarization into an immune-stimulating M1 phenotype and increasing the number of CD8 cytotoxic T to reprogram the immunosuppressive TME. The gene discussed is CD8A; the disease is neoplasm.